



Aurobindo Pharma receives approvals for Cyclobenzaprine Tablets from Health Canada

6th May 2010

Aurobindo Pharma Limited is pleased to announce that it has received the approvals for its Abbreviated New Drug Submission for Cyclobenzaprine Tablets 10mg from Health Canada

Cyclobenzaprine Tablets are the generic equivalent of Canadian reference product Apo-Cyclobenzaprine® tablets of Apotex Inc, Canada and are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

With these approvals Aurobindo now has 12 products approved by Health Canada.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/ product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com